Literature DB >> 1309286

Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study.

R G Simonetti1, C Cammà, F Fiorello, M Cottone, M Rapicetta, L Marino, G Fiorentino, A Craxì, A Ciccaglione, R Giuseppetti.   

Abstract

OBJECTIVE: To determine whether chronic hepatitis C virus (HCV) infection is an independent risk factor for hepatocellular carcinoma and whether it increases the cirrhosis-related risk for hepatocellular carcinoma.
DESIGN: Two pair-matched case-control studies.
SETTING: A referral-based hospital. PATIENTS: In study I, 212 patients with hepatocellular carcinoma (197 of whom had known underlying cirrhosis) were compared with controls who had chronic nonhepatic diseases. In study II, the 197 patients with hepatocellular carcinoma and cirrhosis were compared with 197 pair-matched controls who had cirrhosis but not hepatocellular carcinoma. MEASUREMENTS: Levels of antibody to HCV (anti-HCV), hepatitis B surface antigen (HBsAg), and antibody to hepatitis B core antigen (anti-HBc) were assayed, and alcohol abuse was assessed by history. MAIN
RESULTS: In study I, 151 patients (71%) with hepatocellular carcinoma were anti-HCV positive compared with 11 controls (5%) with chronic nonhepatic diseases (odds ratio, 42; 95% CI, 22 to 95). Multivariate analysis showed that anti-HCV was an independent risk factor for hepatocellular carcinoma (odds ratio, 69; CI, 15 to 308). The analysis also showed that HBsAg (odds ratio, 8.7; CI, 1.5 to 50) and anti-HBc (odds ratio, 4.2 (CI, 1.7 to 11) were risk factors for hepatocellular carcinoma. No statistically significant interaction was found between anti-HCV and the markers of HBV infection. In study II, 146 patients (74%) with hepatocellular carcinoma and cirrhosis were anti-HCV positive compared with 122 patients (62%) with cirrhosis alone (odds ratio, 1.8; CI, 1.1 to 2.8). Multivariate analysis confirmed that anti-HCV (odds ratio, 2.0; CI, 1.3 to 32) and HBsAg (odds ratio, 2.0; CI, 1.0 to 4.2) were independent risk factors for hepatocellular carcinoma.
CONCLUSIONS: Hepatitis C virus infection is a risk factor for hepatocellular carcinoma, apparently by inducing cirrhosis and, to a lesser extent, by enhancing the risk in patients with cirrhosis. Hepatitis C virus infection acts independently of HBV infection (another risk factor) and of alcohol abuse, age, or gender.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309286     DOI: 10.7326/0003-4819-116-2-97

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  63 in total

1.  Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest.

Authors:  Martin R Higgs; Hervé Lerat; Jean-Michel Pawlotsky
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Integrated fibrosis scoring by ultrasonography predicts the occurrence of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

Authors:  Tetsuya Nishiura; Hideaki Watanabe; Koji Yano; Masahiro Ito; Seigo Abiru; Toshifumi Fujimoto; Atsumasa Komori; Hiroshi Yatsuhashi; Yojiro Matsuoka; Hiromi Ishibashi
Journal:  J Med Ultrason (2001)       Date:  2010-10-20       Impact factor: 1.314

3.  Interferon as treatment for acute hepatitis C. A meta-analysis.

Authors:  C Cammà; P Almasio; A Craxì
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

4.  Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy.

Authors:  M J Tong; L P Lai; K Murakami-Mori
Journal:  West J Med       Date:  1997-08

5.  Preventing hepatitis B in people in close contact with hepatocellular carcinoma patients.

Authors:  M W Oberle; C N Shapiro; A P Lanier
Journal:  Public Health Rep       Date:  1997 Jan-Feb       Impact factor: 2.792

6.  Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.

Authors:  J M Jacobson; L Feinman; L Liebes; N Ostrow; V Koslowski; A Tobia; B E Cabana; D Lee; J Spritzler; A M Prince
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

7.  High prevalence of hepatitis C in Egyptian patients with chronic liver disease.

Authors:  I A Waked; S M Saleh; M S Moustafa; A A Raouf; D L Thomas; G T Strickland
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

8.  Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status.

Authors:  Dustin B Stephens; Jennifer R Havens
Journal:  J Stud Alcohol Drugs       Date:  2013-05       Impact factor: 2.582

9.  Association between hepatitis B virus and pancreatic cancer.

Authors:  Manal M Hassan; Donghui Li; Adel S El-Deeb; Robert A Wolff; Melissa L Bondy; Marta Davila; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

10.  A novel small molecule inhibitor of hepatitis C virus entry.

Authors:  Carl J Baldick; Michael J Wichroski; Annapurna Pendri; Ann W Walsh; Jie Fang; Charles E Mazzucco; Kevin A Pokornowski; Ronald E Rose; Betsy J Eggers; Mayla Hsu; Weixu Zhai; Guangzhi Zhai; Samuel W Gerritz; Michael A Poss; Nicholas A Meanwell; Mark I Cockett; Daniel J Tenney
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.